Acute Lymphoblastic Leukemia (ALL) is the most common childhood cancer with approximately 3000 new cases diagnosed in the United States every year, a number that has stayed fairly constant over decades (Mody, 2008). Fortunately, ALL is very responsive to treatment. The prognosis has progressively improved achieving approximately an 80% 10-year-disease-free survival and a 90% 10-year overall survival (OS) probability in the last five years (Devilli, 2021). Most research in the past has looked into the survival rates, chronic illness, and relapse rates of certain treatments for ALL, especially when it comes to pediatric populations. But ALL treatments have been associated with increased risks for adverse outcomes such as late mortality, secondary malignancies, and neurological, cardiac, endocrine, and social/psychological disorders (Kızılocak, 2018). Being that children will have to live with the consequences of cancer for the rest of their lives the long-term effects of the disease and its treatments on the neurological, socioeconomic, and social development of the survivors needs to fully be evaluated. With such a large number of leukemia survivors joining the population every year, it is becoming essential for medical professionals, educators, employers, legislators, and society in general to be aware of the issues faced by the survivors.
| Identifer | oai:union.ndltd.org:bu.edu/oai:open.bu.edu:2144/48105 |
| Date | 14 February 2024 |
| Creators | Batt, Carly |
| Contributors | Bragdon, Beth, Healey, Megan |
| Source Sets | Boston University |
| Language | en_US |
| Detected Language | English |
| Type | Thesis/Dissertation |
Page generated in 0.0021 seconds